Huahai and Jointown have jointly sold 900 million irbesartan tablets and the off-standard market is being squeezed again!

On November 26, Jiuzhoutong issued a notice that Jiuzhoutong and Huahai pharmaceutical, the holding subsidiary of Huahai pharmaceutical, signed the strategic cooperation framework agreement on November 25, 2019, and Huahai pharmaceutical entrusted the company to sell the winning variety "irbesartan tablets" in all channels except 4 + 7 purchasing cities and Fujian and Hebei hospitals, And Kyushu Tong is also responsible for the sales promotion of this channel and the medical distribution guarantee in the provinces selected in the alliance procurement It is understood that the original research drug of irbesartan tablet is ambroside of Sanofi, which was approved by FDA in 1997 The specifications of the marketed products include 75mg, 150mg and 300mg The indications of "irbesartan tablet" are to treat type 2 diabetic nephropathy with essential hypertension and hypertension In the procurement (4 + 7 expansion) of the alliance, irbesartan tablets of Huahai Pharmaceutical Co., Ltd won the bid again, and the quantity to be won is as follows: 4 + 7 extended application of irbesartan tablets of CNOOC Pharmaceutical Co., Ltd won the bid again Jiuzhoutong said that the sales target of the cooperative varieties with Huahai pharmaceutical is 900 million pieces (the number of the winning varieties to be won in the "4 + 7" City drug centralized procurement is 137 million pieces, including 75mg and 150mg specifications), and the agreement is valid from November 1, 2019 to December 31, 2020 The announcement shows that in November 2019, the two sides began to further expand cooperation, establish strategic cooperative relations and achieve win-win goals In the 2020 agreement target, the annual sales target of Huahai pharmaceutical to Jiuzhoutong is 900 million pieces (Jiuzhoutong is responsible for Omni channel sales except for 4 + 7 purchasing cities, Fujian and Hebei hospitals) The purchase in November and December 2019 will be included in the 2020 agreement) In the 4 + 7 expansion, the number of irbesartan tablets of Huahai Pharmaceutical Co., Ltd to win the bid is about 250 million, not counting the number of winning the bid in the first batch of volume procurement Huahai Pharmaceutical Co., Ltd and kyushutong Co., Ltd jointly sell 900 million tablets, basically covering the market outside the centralized mining alliance In this expansion, in addition to Huahai, Hengrui and Hanhui also won the bid for irbesartan tablets Among them, Hanhui's offer is lower than that of Huahai I don't know what the layout of sales channels will be for other winning enterprises, including Hengrui, Hanhui and so on Sina Pharma has analyzed the purchase rules of "centralized document of drug purchase in alliance region" released by Liancai on September 1 The agreed purchase volume of 25 selected varieties in the first year is displayed in the proportion of 50%, 60% and 70%, that is, 50% shares are obtained through exclusive bid winning, 60% shares are obtained by 2 companies and 70% shares are obtained by 3 companies Ideally, the companies that fall the mark can also compete for the remaining 30% - 50% of the market This market is related to the survival of the enterprises that have dropped the standard.